Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bristol-Myers Squibb selects CTLA-4 Probody candidate from collaboration with CytomX

Dec. 14, 2016

MacroGenics and Synthon Biopharmaceuticals sign antibody-drug conjugate agreement

Dec. 14, 2016

EC grants marketing authorization to Arzerra in combination with FC for CLL

Dec. 13, 2016

IGNITE Immunotherapy launches, will focus on oncolytic virus vaccines with lead investor, Pfizer

Dec. 13, 2016

Phase II data show efficacy of pembrolizumab for cutaneous T-cell lymphomas

Dec. 13, 2016

M-DGN-549: a new ADC for cancer

Dec. 13, 2016

BioInvent terminates phase II study of BI-505 in multiple myeloma

Dec. 12, 2016

FDA accepts durvalumab BLA for urothelial cancer

Dec. 12, 2016

Novel bispecific antibody NI-1701 active in B-cell cancer models

Dec. 9, 2016

First-in-human data reported for Merck KGaA's bifunctional immunotherapy antibody

Dec. 9, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...